Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Aug;4(4):282-4.
doi: 10.1111/j.1752-8062.2011.00307.x.

IL28B genotype does not correlate with HIV control in African Americans

Affiliations

IL28B genotype does not correlate with HIV control in African Americans

Mohammad M Sajadi et al. Clin Transl Sci. 2011 Aug.

Erratum in

  • Clin Transl Sci. 2013 Aug;6(4):331

Abstract

Background: HIV-1 natural viral suppressors (NVS) are individuals that control HIV replication without antiretrovirals (also know as HIV elite controllers). We have recently shown that these individuals have an elevated rate of hepatitis C virus (HCV) clearance. Given the association of IL28B genotype, specifically the rs12979860 single nucleotide polymorphism (SNP) based CC genotype, with HCV clearance, we studied its association with HIV control in 172 African American HIV subjects and 173 race-matched controls.

Findings: The frequency of the CC genotype was 12.5% in the NVS, 14.7% in the LVL ("low viral load" cohort with 400-20,000 HIV-1 RNA copies/mL), 17.8% in the MHVL ("medium/high viral load" cohort with >20,000 HIV-1 RNA copies/mL), and 11.6% in an HIV-negative cohort. There was no statistical significance in the CC genotype distribution between these cohorts (p= 0.48 between the NVS and non-NVS HIV positive controls, p= 0.85 between NVS and HIV-negatives). We also did not observe any association between CC genotype distribution and HIV RNA viral load, as a continuous measure.

Conclusions: The IL28B CC genotype does not account for the noted HIV control in our specific NVS cohort. Further studies will be needed to determine if a common genetic factor can primarily account for any joint clearance of HCV and control of HIV.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O’Huigin C, Kidd J, Kidd K, Khakoo SI, Alexander G, et al Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature. 2009; 461(7265): 798–801. - PMC - PubMed
    1. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Heinzen EL, Qiu P, Bertelsen AH, Muir AJ, et al Genetic variation in IL28B predicts hepatitis C treatment‐induced viral clearance. Nature. 2009; 461(7262): 399–401. Epub 2009 Aug 16. - PubMed
    1. Rallón NI, Naggie S, Benito JM, Medrano J, Restrepo C, Goldstein D, Shianna KV, Vispo E, Thompson A, McHutchison J, et al Association of a single nucleotide polymorphism near the interleukin‐28B gene with response to hepatitis C therapy in HIV/hepatitis C virus‐coinfected patients. AIDS. 2010; 24(8): F23–F29. - PMC - PubMed
    1. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, Whitmore TE, Kuestner R, Garrigues U, Birks C, Roraback J, et al IL‐28, IL‐29 and their class II cytokine receptor IL‐28R. Nat Immunol. 2003; 4(1): 63–68. - PubMed
    1. Ma D, Jiang D, Qing M, Weidner JM, Qu X, Guo H, Chang J, Gu B, Shi PY, Block TM, et al Antiviral effect of interferon lambda against West Nile virus. Antiviral Res. 2009; 83(1): 53–60. - PMC - PubMed

Publication types